Ali Ghasemzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Ghasemzadeh has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Amir H. Dorafshar
Division of Plastic and Reconstructive Surgery, Rush University Medical Center, Chicago, IL 60607, USA
5 shared publications - Charles G. Drake
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
5 shared publications Christina M. Kochel
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
5 shared publicationsDebebe Theodros
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
5 shared publicationsDrew M. Pardoll
Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland
5 shared publicationsThomas R. Nirschl
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
5 shared publications
Latest Publications
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF2
Tertiary Lymphoid Structures in Non–Muscle-Invasive Bladder Cancer: Quality over Quantity
High tertiary lymphoid structure (TLS) density predicts favorable outcomes in several solid tumors but worse outcomes in bladder cancer, and the basis for this discrepancy is unclear. In this issue, Péricart and colleagues leverage en bloc resection of non–muscle-invasive bladder tumors to show that TLS accumulate without acquiring the features of productive antitumor immunity. The work reframes TLS in this setting as structures for which functional state, not abundance, dictates their contribution to tumor control. See related article by Péricart et al., p. XX
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF2
Tertiary Lymphoid Structures in Non–Muscle-Invasive Bladder Cancer: Quality over Quantity
High tertiary lymphoid structure (TLS) density predicts favorable outcomes in several solid tumors but worse outcomes in bladder cancer, and the basis for this discrepancy is unclear. In this issue, Péricart and colleagues leverage en bloc resection of non–muscle-invasive bladder tumors to show that TLS accumulate without acquiring the features of productive antitumor immunity. The work reframes TLS in this setting as structures for which functional state, not abundance, dictates their contribution to tumor control. See related article by Péricart et al., p. XX
- 1 November 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (5) , 521-529
Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy
Patients with metastatic renal cell carcinoma (mRCC) with oligometastatic disease can achieve radiographic disease-free (M1 NED) status following cytoreductive nephrectomy and concurrent complete metastasectomy (CNCM). This study aimed to evaluate outcomes and identify risk factors associated with metastatic recurrence and overall survival in mRCC M1 NED patients. Patients with synchronous mRCC who were M1 NED following CNCM from four institutions (2010-2020) were identified. Survival outcomes were analyzed by Kaplan Meier method. Patients were grouped by early (first year following surgery) recurrence or delayed/no known metastatic recurrence. Logistic regression modeling identified risk factors for first-year recurrence and decision curve analysis evaluated the utility of a model incorporating identified risk factors. 109 M1 NED patients were identified including 36 patients who had recurrence in the first year following surgery and 73 patients with delayed or no recurrence. First-year recurrence resulted in significantly shorter overall survival (OS) compared to those with delayed/no recurrence after 1 year (median 15 vs. 97 months respectively, P<0.0001). First-year recurrence predictors included liver metastases, increasing primary tumor size, and elevated preoperative C-reactive protein (CRP). A prognostic model incorporating these factors demonstrated discriminatory capacity and improved clinical decision-making compared to a universal immediate post-operative systemic therapy or active surveillance strategy. Liver metastasis, increasing primary tumor size, and elevated preoperative CRP are associated with increased risk for first-year progression following cytoreductive nephrectomy and complete metastasectomy. Despite radiographic NED status, high risk patients should be considered for immediate systemic therapy following surgery given poor outcomes.
- 1 November 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (5) , 521-529
Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy
Patients with metastatic renal cell carcinoma (mRCC) with oligometastatic disease can achieve radiographic disease-free (M1 NED) status following cytoreductive nephrectomy and concurrent complete metastasectomy (CNCM). This study aimed to evaluate outcomes and identify risk factors associated with metastatic recurrence and overall survival in mRCC M1 NED patients. Patients with synchronous mRCC who were M1 NED following CNCM from four institutions (2010-2020) were identified. Survival outcomes were analyzed by Kaplan Meier method. Patients were grouped by early (first year following surgery) recurrence or delayed/no known metastatic recurrence. Logistic regression modeling identified risk factors for first-year recurrence and decision curve analysis evaluated the utility of a model incorporating identified risk factors. 109 M1 NED patients were identified including 36 patients who had recurrence in the first year following surgery and 73 patients with delayed or no recurrence. First-year recurrence resulted in significantly shorter overall survival (OS) compared to those with delayed/no recurrence after 1 year (median 15 vs. 97 months respectively, P<0.0001). First-year recurrence predictors included liver metastases, increasing primary tumor size, and elevated preoperative C-reactive protein (CRP). A prognostic model incorporating these factors demonstrated discriminatory capacity and improved clinical decision-making compared to a universal immediate post-operative systemic therapy or active surveillance strategy. Liver metastasis, increasing primary tumor size, and elevated preoperative CRP are associated with increased risk for first-year progression following cytoreductive nephrectomy and complete metastasectomy. Despite radiographic NED status, high risk patients should be considered for immediate systemic therapy following surgery given poor outcomes.
- 15 October 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (20) , 5058-5071
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Purpose: In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates tumor-associated draining lymph nodes (DLN), affects adaptive immune responses and combinatorial efficacy of radiotherapy with immune checkpoint blockade (ICB). Experimental Design: We developed a preclinical model to compare stereotactic radiotherapy (Tumor RT) with or without ENI to examine immunologic differences between radiotherapy techniques that spare or irradiate the DLN. Results: Tumor RT was associated with upregulation of an intratumoral T-cell chemoattractant chemokine signature (CXCR3, CCR5-related) that resulted in robust infiltration of antigen-specific CD8+ effector T cells as well as FoxP3+ regulatory T cells (Tregs). The addition of ENI attenuated chemokine expression, restrained immune infiltration, and adversely affected survival when combined with ICB, especially with anti-CLTA4 therapy. The combination of stereotactic radiotherapy and ICB led to long-term survival in a subset of mice and was associated with favorable CD8 effector-to-Treg ratios and increased intratumoral density of antigen-specific CD8+ T cells. Although radiotherapy technique (Tumor RT vs. ENI) affected initial tumor control and survival, the ability to reject tumor upon rechallenge was partially dependent upon the mechanism of action of ICB; as radiotherapy/anti-CTLA4 was superior to radiotherapy/anti-PD-1. Conclusions: Our results highlight that irradiation of the DLN restrains adaptive immune responses through altered chemokine expression and CD8+ T-cell trafficking. These data have implications for combining radiotherapy and ICB, long-term survival, and induction of immunologic memory. Clinically, the immunomodulatory effect of the radiotherapy strategy should be considered when combining stereotactic radiotherapy with immunotherapy. Clin Cancer Res; 24(20); 5058–71. ©2018 AACR.
- 15 October 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (20) , 5058-5071
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Purpose: In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates tumor-associated draining lymph nodes (DLN), affects adaptive immune responses and combinatorial efficacy of radiotherapy with immune checkpoint blockade (ICB). Experimental Design: We developed a preclinical model to compare stereotactic radiotherapy (Tumor RT) with or without ENI to examine immunologic differences between radiotherapy techniques that spare or irradiate the DLN. Results: Tumor RT was associated with upregulation of an intratumoral T-cell chemoattractant chemokine signature (CXCR3, CCR5-related) that resulted in robust infiltration of antigen-specific CD8+ effector T cells as well as FoxP3+ regulatory T cells (Tregs). The addition of ENI attenuated chemokine expression, restrained immune infiltration, and adversely affected survival when combined with ICB, especially with anti-CLTA4 therapy. The combination of stereotactic radiotherapy and ICB led to long-term survival in a subset of mice and was associated with favorable CD8 effector-to-Treg ratios and increased intratumoral density of antigen-specific CD8+ T cells. Although radiotherapy technique (Tumor RT vs. ENI) affected initial tumor control and survival, the ability to reject tumor upon rechallenge was partially dependent upon the mechanism of action of ICB; as radiotherapy/anti-CTLA4 was superior to radiotherapy/anti-PD-1. Conclusions: Our results highlight that irradiation of the DLN restrains adaptive immune responses through altered chemokine expression and CD8+ T-cell trafficking. These data have implications for combining radiotherapy and ICB, long-term survival, and induction of immunologic memory. Clinically, the immunomodulatory effect of the radiotherapy strategy should be considered when combining stereotactic radiotherapy with immunotherapy. Clin Cancer Res; 24(20); 5058–71. ©2018 AACR.
- 1 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (4) , 422-433
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
The cGAS–STING cytosolic DNA sensing pathway may play an integral role in the initiation of antitumor immune responses. Studies evaluating the immunogenicity of various cyclic dinucleotide (CDN) STING agonists administered by intratumoral (i.t.) injection showed potent induction of inflammation, tumor necrosis, and, in some cases, durable tumor-specific adaptive immunity. However, the specific immune mechanisms underlying these responses remain incompletely defined. The majority of these studies have focused on the effect of CDNs on immune cells but have not conclusively interrogated the role of stromal cells in the acute rejection of the CDN-injected tumor. Here, we revealed a mechanism of STING agonist-mediated tumor response that relied on both stromal and immune cells to achieve tumor regression and clearance. Using knockout and bone marrow chimeric mice, we showed that although bone marrow–derived TNFα was necessary for CDN-induced necrosis, STING signaling in radioresistant stromal cells was also essential for CDN-mediated tumor rejection. These results provide evidence for crosstalk between stromal and hematopoietic cells during CDN-mediated tumor collapse after i.t. administration. These mechanistic insights may prove critical in the clinical development of STING agonists. Cancer Immunol Res; 6(4); 422–33. ©2018 AACR.
- 1 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (4) , 422-433
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
The cGAS–STING cytosolic DNA sensing pathway may play an integral role in the initiation of antitumor immune responses. Studies evaluating the immunogenicity of various cyclic dinucleotide (CDN) STING agonists administered by intratumoral (i.t.) injection showed potent induction of inflammation, tumor necrosis, and, in some cases, durable tumor-specific adaptive immunity. However, the specific immune mechanisms underlying these responses remain incompletely defined. The majority of these studies have focused on the effect of CDNs on immune cells but have not conclusively interrogated the role of stromal cells in the acute rejection of the CDN-injected tumor. Here, we revealed a mechanism of STING agonist-mediated tumor response that relied on both stromal and immune cells to achieve tumor regression and clearance. Using knockout and bone marrow chimeric mice, we showed that although bone marrow–derived TNFα was necessary for CDN-induced necrosis, STING signaling in radioresistant stromal cells was also essential for CDN-mediated tumor rejection. These results provide evidence for crosstalk between stromal and hematopoietic cells during CDN-mediated tumor collapse after i.t. administration. These mechanistic insights may prove critical in the clinical development of STING agonists. Cancer Immunol Res; 6(4); 422–33. ©2018 AACR.
- Open Access
- 4 December 2017
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 21 (1) , 113-125
Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
Background Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare—potentially due to low baseline levels of infiltration. Using an immunocompetent cMyc-driven model (Myc-CaP), we sought to understand the immune infiltrate induced by androgen deprivation therapy (ADT) and to leverage that infiltration toward therapeutic benefit. Methods Using flow cytometry, qPCR and IHC, we quantified ADT-induced immune infiltration in terms of cell type and function. Preclinical treatment studies tested the combinatorial effects of ADT and immune checkpoint blockade using tumor outgrowth and overall survival as end points. Results ADT induces a complex pro-inflammatory infiltrate. This pro-inflammatory infiltrate was apparent in the early postcastration period but diminished as castration resistance emerged. Combining ADT with tumor-infiltrating regulatory T cell (Treg) depletion using a depleting anti-CTLA-4 antibody significantly delayed the development of castration resistance and prolonged survival of a fraction of tumor-bearing mice. Immunotherapy as a monotherapy failed to provide a survival benefit and was ineffective if not administered in the peri-castration period. Conclusions The immune infiltrate induced by ADT is diverse and varies over time. Therapeutic strategies focusing on depleting Tregs in the peri-castration period are of particular interest.
- 4 December 2017
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 21 (1) , 113-125
Open AccessCombining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
Background Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare—potentially due to low baseline levels of infiltration. Using an immunocompetent cMyc-driven model (Myc-CaP), we sought to understand the immune infiltrate induced by androgen deprivation therapy (ADT) and to leverage that infiltration toward therapeutic benefit. Methods Using flow cytometry, qPCR and IHC, we quantified ADT-induced immune infiltration in terms of cell type and function. Preclinical treatment studies tested the combinatorial effects of ADT and immune checkpoint blockade using tumor outgrowth and overall survival as end points. Results ADT induces a complex pro-inflammatory infiltrate. This pro-inflammatory infiltrate was apparent in the early postcastration period but diminished as castration resistance emerged. Combining ADT with tumor-infiltrating regulatory T cell (Treg) depletion using a depleting anti-CTLA-4 antibody significantly delayed the development of castration resistance and prolonged survival of a fraction of tumor-bearing mice. Immunotherapy as a monotherapy failed to provide a survival benefit and was ineffective if not administered in the peri-castration period. Conclusions The immune infiltrate induced by ADT is diverse and varies over time. Therapeutic strategies focusing on depleting Tregs in the peri-castration period are of particular interest.
- 31 October 2017
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 5 (11) , 992-1004
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment
Radiotherapy (RT) enhances innate and adaptive antitumor immunity; however, the effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the tumor microenvironment (TME) are not fully elucidated. Although previous reports suggest an increased Treg infiltration after radiation, whether these Tregs are functionally suppressive remains undetermined. To test the hypothesis that RT enhances the suppressive function of Treg in the TME, we selectively irradiated implanted tumors using the small animal radiation research platform (SARRP), which models stereotactic radiotherapy in human patients. We then analyzed tumor-infiltrating lymphocytes (TIL) with flow-cytometry and functional assays. Our data showed that RT significantly increased tumor-infiltrating Tregs (TIL-Treg), which had higher expression of CTLA-4, 4-1BB, and Helios compared with Tregs in nonirradiated tumors. This observation held true across several tumor models (B16/F10, RENCA, and MC38). We found that TIL-Tregs from irradiated tumors had equal or improved suppressive capacity compared with nonirradiated tumors. Our data also indicated that after RT, Tregs proliferated more robustly than other T-cell subsets in the TME. In addition, after RT, expansion of Tregs occurred when T-cell migration was inhibited using Fingolimod, suggesting that the increased Treg frequency was likely due to preferential proliferation of intratumoral Treg after radiation. Our data also suggested that Treg expansion after irradiation was independent of TGFβ and IL33 signaling. These data demonstrate that RT increased phenotypically and functionally suppressive Tregs in the TME. Our results suggest that RT might be combined effectively with Treg-targeting agents to maximize antitumor efficacy. Cancer Immunol Res; 5(11); 992–1004. ©2017 AACR.
- 31 October 2017
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 5 (11) , 992-1004
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment
Radiotherapy (RT) enhances innate and adaptive antitumor immunity; however, the effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the tumor microenvironment (TME) are not fully elucidated. Although previous reports suggest an increased Treg infiltration after radiation, whether these Tregs are functionally suppressive remains undetermined. To test the hypothesis that RT enhances the suppressive function of Treg in the TME, we selectively irradiated implanted tumors using the small animal radiation research platform (SARRP), which models stereotactic radiotherapy in human patients. We then analyzed tumor-infiltrating lymphocytes (TIL) with flow-cytometry and functional assays. Our data showed that RT significantly increased tumor-infiltrating Tregs (TIL-Treg), which had higher expression of CTLA-4, 4-1BB, and Helios compared with Tregs in nonirradiated tumors. This observation held true across several tumor models (B16/F10, RENCA, and MC38). We found that TIL-Tregs from irradiated tumors had equal or improved suppressive capacity compared with nonirradiated tumors. Our data also indicated that after RT, Tregs proliferated more robustly than other T-cell subsets in the TME. In addition, after RT, expansion of Tregs occurred when T-cell migration was inhibited using Fingolimod, suggesting that the increased Treg frequency was likely due to preferential proliferation of intratumoral Treg after radiation. Our data also suggested that Treg expansion after irradiation was independent of TGFβ and IL33 signaling. These data demonstrate that RT increased phenotypically and functionally suppressive Tregs in the TME. Our results suggest that RT might be combined effectively with Treg-targeting agents to maximize antitumor efficacy. Cancer Immunol Res; 5(11); 992–1004. ©2017 AACR.
- 1 December 2016
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (12) , 1366-1381
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFβ1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo. The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFβ1′s previously known effects on T-cell function, our findings suggest that TGFβ1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFβ-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity. Significance: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFβ and demonstrate that TGFβ1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366–81. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1293
- 1 December 2016
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (12) , 1366-1381
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFβ1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo. The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFβ1′s previously known effects on T-cell function, our findings suggest that TGFβ1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFβ-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity. Significance: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFβ and demonstrate that TGFβ1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366–81. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1293
- Open Access
- 4 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 74
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
[This corrects the article DOI: 10.1186/s40425-016-0132-2.].
- 4 November 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 74
Open AccessErratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
[This corrects the article DOI: 10.1186/s40425-016-0132-2.].
- Open Access
- 17 May 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 28
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
According to National AIDS Control Organization of India, NACO, in 2003 there were 530,000 new HIV infections in India with women accounting for a significant number. This raises the issue of HIV prevalence among pregnant women and the transfer of HIV from mother to child (MTCT) especially in states such as Tamil Nadu where the HIV prevalence rates among pregnant women exceeds 1%1. To prevent MTCT various voluntary counseling and testing (VCT) programs have been implemented but baseline data regarding knowledge, attitude and practice towards HIV/AIDS among the pregnant women in many of the regions is lacking. The goal of this study was to determine the general baseline knowledge regarding HIV/AIDS along with attitudes and practices towards HIV/AIDS among rural women in the Namakkal district presenting for antenatal care at government health facilities. Our results show that about 50% of the women did not think or did not know that HIV transmission from person to person can be prevented and also about 60% of the women did not think or know that MTCT can be prevented. Almost 90% of the women did not know where they can get testing for HIV and 80% did not know where they can go to receive PMTCT services. The majority of the women (70%) indicated they would accept medication to reduce MTCT, however only 32% were willing to accept HIV testing if pregnant. These findings help to identify the gaps in knowledge regarding HIV/AIDS among pregnant women and the barriers they face. Future VCT sessions need to take these factors into consideration to overcome such barriers and to increase the effectiveness of VCT and to reduce MTCT.
- 17 May 2016
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1) , 28
Open AccessAgonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
According to National AIDS Control Organization of India, NACO, in 2003 there were 530,000 new HIV infections in India with women accounting for a significant number. This raises the issue of HIV prevalence among pregnant women and the transfer of HIV from mother to child (MTCT) especially in states such as Tamil Nadu where the HIV prevalence rates among pregnant women exceeds 1%1. To prevent MTCT various voluntary counseling and testing (VCT) programs have been implemented but baseline data regarding knowledge, attitude and practice towards HIV/AIDS among the pregnant women in many of the regions is lacking. The goal of this study was to determine the general baseline knowledge regarding HIV/AIDS along with attitudes and practices towards HIV/AIDS among rural women in the Namakkal district presenting for antenatal care at government health facilities. Our results show that about 50% of the women did not think or did not know that HIV transmission from person to person can be prevented and also about 60% of the women did not think or know that MTCT can be prevented. Almost 90% of the women did not know where they can get testing for HIV and 80% did not know where they can go to receive PMTCT services. The majority of the women (70%) indicated they would accept medication to reduce MTCT, however only 32% were willing to accept HIV testing if pregnant. These findings help to identify the gaps in knowledge regarding HIV/AIDS among pregnant women and the barriers they face. Future VCT sessions need to take these factors into consideration to overcome such barriers and to increase the effectiveness of VCT and to reduce MTCT.
- Open Access
- 14 February 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (4) , 793-801
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development. Clin Cancer Res; 22(4); 793–801. ©2015 AACR.
- 14 February 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (4) , 793-801
Open AccessNew Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development. Clin Cancer Res; 22(4); 793–801. ©2015 AACR.